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Abstract
Background: The HLA genes, located in the MHC region on chromosome 6p21.3, play an important role in many
autoimmune disorders, such as celiac disease (CD), type 1 diabetes (T1D), rheumatoid arthritis, multiple sclerosis, psoriasis
and others. Known HLA variants that confer risk to CD, for example, include DQA1*05/DQB1*02 (DQ2.5) and DQA1*03/
DQB1*0302 (DQ8). To diagnose the majority of CD patients and to study disease susceptibility and progression, typing these
strongly associated HLA risk factors is of utmost importance. However, current genotyping methods for HLA risk factors
involve many reactions, and are complicated and expensive. We sought a simple experimental approach using tagging
SNPs that predict the CD-associated HLA risk factors.
Methodology: Our tagging approach exploits linkage disequilibrium between single nucleotide polymorphism (SNPs) and
the CD-associated HLA risk factors DQ2.5 and DQ8 that indicate direct risk, and DQA1*0201/DQB1*0202 (DQ2.2) and
DQA1*0505/DQB1*0301 (DQ7) that attribute to the risk of DQ2.5 to CD. To evaluate the predictive power of this approach,
we performed an empirical comparison of the predicted DQ types, based on these six tag SNPs, with those executed with
current validated laboratory typing methods of the HLA-DQA1 and -DQB1 genes in three large cohorts. The results were
validated in three European celiac populations.
Conclusion: Using this method, only six SNPs were needed to predict the risk types carried by .95% of CD patients. We
determined that for this tagging approach the sensitivity was .0.991, specificity .0.996 and the predictive value .0.948.
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD.
This method is broadly applicable in European populations.
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Introduction
The HLA genes, located in the major histocompatibility (MHC)
region on chromosome 6p21.3, play a role in multiple autoimmune
disorders, like celiac disease (CD), type 1 diabetes (T1D), rheumatoid
arthritis, multiple sclerosis, psoriasis and others [1–3]. The MHC
region is highly polymorphic and some genes in this region are
involved in multiple disorders. For example, the HLA-DQA1 and
-DQB1 genes have alleles that confer risk to both CD and T1D. In
most autoimmune diseases not all patients carry the same risk alleles,
and multiple risk alleles are likely to be involved [2].
CD, the most common intolerance to a dietary component in
Western society, is sustained by an abnormal T cell response to
gluten as an environmental factor and is strongly associated with
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HLA class II genes. Almost 95% of CD patients carry at least one
of the two risk molecules DQA1*05/DQB1*02 (i.e. haplotype
DQ2.5) and DQA1*03/DQB1*0302 (i.e. haplotype DQ8) [2,4–
7]. The molecules encoded by the CD-associated HLA-DQA1 and
-DQB1 genes form DQa and DQb heterodimers, which can lead to
several functional molecules of which one to four copies can be
made. A few variants of these genes predispose to CD (either alone or
in combination) when gluten peptides, present in wheat, barley and
rye, are presented to CD4+ cells in the lamina propria [8,9]. The
most important risk factor for CD is the DQ2.5 haplotype (see
Figure 1 and Table 1) [5,10,11], with the highest risk in individuals
homozygous for this haplotype [8,12], or those who have a single
copy of DQ2.5 and one copy of DQA1*0201/DQB1*0202 (i.e.
haplotype DQ2.2) molecules, haplotype DQ8, or DQA1*0505/
DQB1*0301 (i.e. haplotype DQ7). The frequency of these alleles in
the general population is substantial (.25%), suggesting that these
variants are necessary for disease development but not sufficient.
Family-based or population-based screening for the CD risk
variants has important diagnostic value in supporting the diagnosis
of CD when these alleles are present, and the possibility of CD is
minimized when they are not present (they have a high negative
predictive value). In a recent study by Bourgey et al. [13] it was
shown that the risk estimates of a sibling of a CD patient ranges
from 0.1% to 29% when HLA-DQ information is included,
compared to the overall risk for sibs of approx. 10%. CD affects
almost 1% of the population, although it is estimated that most
cases remain undiagnosed [14]. Since untreated CD can cause
long-term health problems, targeted screening in e.g. families for
CD could identify such undiagnosed individuals and prevent life-
long symptoms and complications.
Testing for HLA risk molecules is routinely performed using
specialized kits, but they often require 24–60 reactions, multiple
steps, like amplification and hybridization to a membrane, special
software or expertise in analyzing the results and most of these
methods are expensive (e.g. DNA PCR-single-strand conformation
polymorphism (PCR-SSCP) [15], PCR and sequence specific
oligonucleotide probing (PCR-SSOP) [16], PCR-sequence specific
primer kits (PCR-SSP [17], PCR-reverse line blot (PCR-RLB) [18]).
Direct typing of the genetic variants that encode the HLA alleles is
usually very difficult since most of these variants are surrounded by
too many other variants that interfere with primer annealing.
The International HapMap Project and an independent MHC-
focused effort [19,20] have empirically determined the fine-scale
patterns of linkage disequilibrium (LD) among local sequence
polymorphisms in four population samples. With these resources it
is now possible to pick tag SNPs that are in LD with specific HLA
variants of interest (i.e. have high r2 values). Recently, an LD-
based tagging approach was shown to predict HLA-DQ2.2 and –
DQ2.5 alleles in independent patient samples with a high degree
of accuracy [20].
In this study we selected tag SNPs to predict DQ2.2, DQ2.5,
DQ7 and DQ8, in three cohorts: CD patients, non-CD trio
control families, and blood bank controls (HLA typing was
available for all individuals). We then examined the sensitivity,
specificity, predictive value and the correlation between the SNP-
based test and the true HLA variant (r2). This study represents a
first step towards providing a cost-effective population screening
method for CD.
Results
A total of six SNPs were needed to predict the DQ2.2, DQ2.5,
DQ7 and DQ8 risk types for CD. Typing was done in three
different cohorts comprising a total of 754 persons (1512 alleles).
Dropout rates for these SNPs were ,3.3% as described in Table
S1. All SNPs were in Hardy-Weinberg equilibrium and no
Mendelian errors were observed in the trios.
We observed a high correlation between the three cohorts for
the sensitivity, specificity, PPV and the r2. We grouped the results
of the three different cohorts (Table 2) and show the results of each
separate group in Table S2. Specifications of the individuals of
whom the predicted HLA-DQ typing results did not correspond
with those from the typing centres are shown in Table S3. For all
false-positive and false-negative typings, the SNPs were retyped
and all official typings were either double checked or retyped.
However it was not always possible to use DNA from one tube for
Figure 1. HLA-DQA1* and -DQB1* together form heterodimers
of which DQ2.5 and DQ8, either in homozygous or heterozy-
gous state, confer risk to CD due to their ability to present
gluten to T cells. DQ2.2 and DQ7 can only confer risk to CD when
both are present together or with DQ2.5 (trans effect, see dashed lines).
See Table 1 for the possible combinations, the number of risk molecules
and the associated risk.
doi:10.1371/journal.pone.0002270.g001
Table 1. Genetic risk associated with the different HLA-DQ
molecules
DQ molecule 1 DQ molecule 2
Number of
functional copies
Genetic
risk
DQ2.5 Non-CD risk types $1 5.5
DQ2.5 DQ2.5 4 13.1
DQ2.5 no DQ2.2, DQ2.5, DQ7 1 1.3
DQ2.5 no DQ2.5 1–2 2.5
DQ2.5 DQ2.2 2 10.1
DQ2.2 or DQ2.5 Non-CD risk types 1–4 24.4
DQ2.2 DQ7 1 1.8*
DQ2.2 no DQ2.5, DQ7 0 -
DQ7 no DQ2.2, DQ2.5 0 -
DQ2.5 DQ7 2 -
DQ8 Non-CD risk types 1 -
DQ8 DQ8 4 -
b) Combinations of the DQ molecules on the two chromosomes, the number of
functional copies and the genetic risk associated to coeliac disease (calculated
using the CD cohort and the blood bank control cohort).
*This risk increases to 4.1 in the DQ2.5 negative group.
doi:10.1371/journal.pone.0002270.t001
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both the SNP retyping and official retyping, so we cannot fully rule
out the possibility of DNA switching leading to false-positive or
false-negative results.
For each DQ type we used all persons with non-missing data for
the relevant SNPs. A person with missing data for DQ2.5, for
example, was excluded from the DQ2.5 analysis, but could be
used for the other analyses if genotypes relevant for the other DQ
types were present.
At first the sensitivity and specificity for DQ2.2 was high and
accurate but the predictive value was low. The SNPs for DQ2.2
(rs2395182, rs7775228) not only tagged DQ2.2 but also included
the relatively infrequent DQ4 allele. We therefore decided to tag
DQ4 as well (rs4713586) making it possible to call a person DQ2.2
when the alleles were positive for DQ2.2 and negative for DQ4.
This led to three tag SNPs being needed for the prediction of
DQ2.2, with an overall sensitivity of 0.992, a specificity of 0.998
and a PPV of 0.977. Only four of the 1448 tested chromosomes
gave false results (0.28%).
The tag SNP selected for prediction of DQ2.5 (rs2187668)
showed an overall sensitivity of 1.000, a specificity of 0.999 and a
PPV of 0.998. Only one of the 1458 tested chromosomes gave false
results (0.07%). This person did indeed carry half of the DQ2.5
haplotype (DQA1*0501) (see Table S3b, person no. 10).
The tag SNP for DQ7 (rs4639334) showed an overall sensitivity
of 1.000, a specificity of 0.997 and a PPV of 0.959. Four of the
1470 tested chromosomes gave false results (0.27%), of which three
carried a rare haplotype consisting of half of the DQ7 haplotype.
Two of these three carried a combination of the DQA1*0505
allele of DQ7 with the DQB1*0302 of DQ8 (see results of DQ8 as
well) and were predicted to be both DQ7 and DQ8 (see Table
S3b, person nos. 11 and 12). For one of these persons we typed the
parents and we could see a transmission of this combined
haplotype in the family.
The tag SNP for DQ8 (rs7454108) showed an overall sensitivity
of 0.991, a specificity of 0.996 and a PPV of 0.948. Seven of the
1484 tested chromosomes gave false results (0.5%).
Accepting the prediction of these half haplotypes as good
predictions of the risk alleles increases the sensitivity, specificity
and PPV slightly.
To validate our results in other populations, we additionally
tested the same SNP panel in 76 HLA-typed individuals from the
‘‘preventCD’’ study populations (a family based celiac disease
study) from Valencia (Spain) (n = 32) and Naples (Italy) (n = 44). In
addition, we previously reported on the performance of the DQ2.5
predictive SNP rs2187668 SNP in 262 HLA-typed celiac cases
from the UK as part of a genome-wide association study [23]. The
overall sensitivity and specificity in the UK celiac population was
similar to what was observed in the Dutch celiac population. In the
Spanish and Italian celiac cohort a few samples showed
discordance for the DQ2.5 and DQ7 haplotype, giving rise to
slightly lower r2 values for this prediction. Prediction values for
DQ2.2 and DQ8 in both Spanish and Italian celiac samples were
similar to the Dutch results (Table S4).
Discussion
In this study we used a tag SNP approach to predict whether an
individual carried the risk DQ types (formed by variants in the HLA-
DQA1 and -DQB1 genes) that are positively associated with CD.
Using this method, only six SNPs were needed to predict the DQ2.2,
DQ2.5, DQ7 and DQ8 risk types carried by.95% of CD patients.
We determined that for this tagging approach the sensitivity was
.0.991, specificity .0.996 and the predictive value .0.948.
Most of the patients without DQ2.5 and DQ8, carried half of
the DQ2.5 or DQ2.2 molecule (either HLA-DQA1*05 or
-DQB1*0202) suggesting that carrying part of the risk molecules
has functional implications for the risk of CD [4,22]. Of our
patient group 98.4% carry one of the risk groups (DQ2.2, DQ2.5,
DQ7, DQ8 or the DQ types that have half of the risk haplotypes)
and 98.3% of all patients were correctly predicted using our
method. Overall, the sensitivity was 0.997, the specificity was
.0.929 and predictive value was .0.987 when taking into
account that some of the false predictions included an allele that is
part of a risk haplotype (e.g. the HLA-DQA1*05 allele which is
part of the DQ2.5 haplotype, see person nos. 10–12 in Table S3b).
This method also allowed us to determine whether an individual
was homozygous or heterozygous for the risk molecule. Vader et
al. demonstrated a.4-fold higher T cell response when gluten was
presented by antigen-presenting cells from DQ2 homozygous
patients compared to DQ2 heterozygous patients, thereby
providing an explanation for the dose-effect of risk molecules for
developing CD [9]. Al-Toma et al. showed that homozygosity for
DQ2.5 was seen more than twice as often in individuals that
developed refractory celiac disease and enteropathy-associated T-
cell lymphoma, associated with a high morbidity, than in
uncomplicated CD [12].
Reinton et al. developed a real-time PCR method for detecting
CD-associated HLA risk alleles [23]. This method requires 11
reactions and even more if homozygous persons for the HLA-risk
alleles need to be distinguished from heterozygous persons. It is
not clear whether this real-time PCR method can be easily applied
to high-throughput typing or not, whereas our method can. We
can perform PCR reactions in multiple PCR machines at the same
time and use the ABI PRISM 7900 HT system only for end-point
measurements. Moreover, Reinton et al. only used a relatively
small set of samples to test their method, making it difficult to
determine its robustness.
Table 2. Prediction results for combined cohorts
DQ2.2
+ 2 total sensitivity 0.992
SNP prediction + 126 3 129 specificity 0.998
2 1 1318 1319 positive predictive value 0.977
total 127 1321 1448 r-squared 0.966
DQ2.5
+ 2 total sensitivity 1.000
SNP prediction + 569 1 570 specificity 0.999
2 0 888 888 positive predictive value 0.998
total 569 889 1458 r-squared 0.997
DQ7
+ 2 total sensitivity 1.000
SNP prediction + 94 4 98 specificity 0.997
2 0 1372 1372 positive predictive value 0.959
total 94 1376 1470 r-squared 0.956
0.069
DQ8
+ 2 total sensitivity 0.991
SNP prediction + 110 6 116 specificity 0.996
2 1 1367 1368 positive predictive value 0.948
total 111 1373 1484 r-squared 0.935
doi:10.1371/journal.pone.0002270.t002
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De Bakker et al. showed two examples that used the tagging
method for CD and systemic lupus erythematosus [20]. They chose
two SNPs to capture DQ2.2 and DQ2.5 in the same CD cohort
(N=330) that we have used in this paper. The rs4988889(T),
rs2858331(C) haplotype was used to determine the presence of
DQ2.2 and the rs4988889(T), rs2858331(T) haplotype was used to
determine DQ2.5. Although the SNPs look promising in determin-
ing DQ2.5 homozygosity or DQ2.2/DQ2.5 heterozygosity, it was
often difficult to distinguish DQ2.2/X heterozygous from the
DQ2.5/X heterozygous individuals (X is any other allele excluding
DQ2.2 or DQ2.5), due to phase uncertainty of the alleles at the two
SNPs. An individual who is heterozygous for rs4988889 (G/T) has
one copy of DQ2.2 or DQ2.5. If he/she is also heterozygous for
rs2858331 (C/T), then it is uncertain which of these alleles (either C
or T) is on the same chromosome as the T allele of rs498889, and
therefore forms either DQ2.2 or DQ2.5. In contrast to these
examples are the SNPs we used in the current study, which are
capable of determining whether an individual is homozygous for
DQ2.2 or DQ2.5, heterozygous for DQ2.2 or DQ2.5, or does not
possess the DQ2.2 or DQ2.5 haplotype at all.
We expect the chosen tag SNPs to be transferable within
European populations given the strong conservation of the HLA-
DR3-DQ2 haplotype. De Bakker et al. has given two examples
that show that tag SNPs chosen from the CEU panel (CEPH
(Utah residents with ancestry from northern and western Europe))
are applicable in other populations and our data also gives similar
r2 values to the CEU panel [20]. The r2 might be somewhat higher
or lower in the population that it is applied to, with a resulting gain
or loss of power, but the differences observed are minimal. We
have also seen that the tag SNP for DQ2.5 tested in an UK
population gives comparable results (UK population: r2 0.96,
Dutch population: r2 0.99) [21]. Analysing the tag SNPs in two
southern European populations – from Italy and Spain – gives
lower r2 values compared to the Dutch, especially for the DQ2.5
and DQ7 genotypes. Overall, however, both populations show
high sensitivity and specificity. The lower r2 values in the Spanish
and Italian populations could be caused by the presence of rare
southern Europe-specific haplotypes, or due to inaccuracies of the
original HLA II DQ2 and DQ8 haplotype identification by an
SSP-based method. The few false-negative or false-positive
predictions observed in the Dutch celiac population may also be
explained by the presence of rare haplotypes. The transferability of
this method in populations that have known differences in LD
structure, like African, Japanese, Chinese, still needs to be
determined. The six SNPs should be tested in these populations
and, using the data of de Bakker et al., other tag SNPs might be
found that perform equally or perhaps better than the six SNPs
presented in this paper [20].
Our method is attractive because it is cost-effective and the
experimental procedures are straightforward, using routine
genotyping equipment. Although more work is needed to validate
this approach for diagnostic purposes, our work provides a
foundation for simple SNP-based population screening for CD.
Population screening has been discussed for a long time and it
would certainly be helpful in finding all the undiagnosed CD
patients, which could prevent negative outcomes [14]. However
no steps have actually been taken towards implementing it largely
due to the cost of classical HLA typing and the need to repeat
serology tests during an individual’s lifetime. Since an individual
can develop antibodies to CD later in life, repeated testing would
impose an extra burden on people who might not be at any risk. It
would be easy, cheap and quick to use our tag SNP method to
determine which part of the population (,25%) needs to be
screened more extensively for CD. As this test requires very little
DNA and is fairly insensitive to DNA quality, it can also be used
with DNA material isolated from e.g. biopsies, whole-genome
amplified DNA, and DNA isolated from FTA cards. Furthermore,
this test determines which individuals are not at risk for developing
CD and who therefore do not need further serology tests.
We have described a robust method to predict the risk DQ types
involved in CD with high accuracy. This method can also be
applied to T1D, in which DQ2.5 and DQ8 are also known risk
factors, or more generally for other immune-related diseases with
known HLA risk alleles.
Materials and Methods
DNA samples
DNA was available from three different cohorts; these were used
to study different aspects of the tag SNP method. The CD cohort
had a high number of individuals with HLA-DQ2 risk variants,
which was useful for testing the positive predictive value. The trio
control cohort enabled us to check for Mendelian errors (which
were not observed). while the blood bank controls gave a better
view of the robustness of the method in the general population.
The first cohort consisted of 330 unrelated CD patients of Dutch
Caucasian origin [24]. Only CD patients diagnosed according to
revised ESPGHAN criteria and with a Marsh III lesion confirmed
by duodenal biopsy sampling were selected for this study, as
described by Van Belzen et al. [25] and Walker-Smith et al. [26].
A cohort of population-based control trios was derived from
families without a history of CD [27]. The 86 control trios were
selected for the presence of at least one parent carrying haplotype
DQ2.5 and were all of Dutch Caucasian origin. HLA typing data
was available for 207 of the 264 persons in the 86 trios (see below),
of these 2 persons dropped out for all SNPs typed and were
excluded from this paper. The blood bank cohort was part of the
ITI two panel (the ITI panel is a DNA panel from the
Immunogenetics and Transplantation Immunology Section of
the LUMC) and consisted of 219 unrelated, randomly selected,
Dutch blood donors. We studied a total of 754 persons. The study
was approved by the Medical Ethics Committee of the University
Medical Centre Utrecht, and informed consent was obtained from
the participants.
The replication cohort includes 32 HLA-typed Spanish celiac
samples from Valencia and 44 HLA-typed Italian celiac samples
from Naples. These two study samples form part of the
‘‘preventCD’’ study, a European multicenter study. The 262
HLA-typed UK celiac cases were recently included in a genome-
wide association study [21].
HLA typing
The CD cohort and the trio control cohort were typed for HLA-
DQA1 and -DQB1 genes using a classical PCR-SSCP/heterodu-
plex method in an official HLA typing laboratory as described
elsewhere [12,15]. Full HLA-DQA1 and -DQB1 typing was
available for the entire CD cohort. For the trio control cohort, full
HLA-DQA1 and -DQB1 typing was available for the child and
both parents in 34 trios and for the child and one of the parents in
51 trios, and for one trio only one person could be SNP typed
leading to a total of 205 persons available for analyses. For the
blood bank control cohort, full (four digit) HLA-DRB1, -DQA1
and -DQB1 typing was performed by PCR-SSCP using locally
produced and slightly modified primer mixes [28]. The typing of
this cohort was performed in the European Foundation of
Immunogenetics (EFI)-accredited HLA laboratory of the Depart-
ment of IHB, LUMC, Leiden. The typing of UK samples were
performed at the Transplant Immunology laboratory, Oxford
Celiac HLA Risk Allele Test
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Radcliffe Hospitals NHS Trust using the PCR-SSCP method. The
Italian and Spanish samples were HLA typed by Eurospital (Italy)
using the Eu-DQ kit.
Tag SNP selection
Tag SNPs were selected that captured the following HLA types:
DQ2.2 (2 SNPs for DQ2.2 and one SNP to exclude DQ4 from the
DQ2.2 group), DQ2.5 (1 SNP), DQ7 (1 SNP), and DQ8 (1 SNP)
(see Table 3). DQ2.5 and DQ8 are risk factors for CD and are
carried by ,95% of CD patients [4,22]. The HLA-DQA1*0505
allele of DQ7 and HLA-DQA1*0501 allele of DQ2.5 only differ
by one or a few base pairs and are thought to have the same
functional properties. This also holds for the HLA-DQB1*0202
allele of DQ2.2 and the HLA-DQB1*0201 allele of DQ2.5. Most
of the CD patients who do not carry DQ2.5 or DQ8, carry half of
the DQ2.5 or DQ2.2 molecule (that is either HLA-DQA1*05 or -
DQB1*0202) suggesting that carrying part of the risk molecules
has functional implications for the risk of CD [4].
Tag SNP selection was based on genotype data collected in the
classical HLA genes and .7,500 common SNP and deletion-
insertion polymorphisms across the extended human MHC region
[20]. We used Tagger [29] to derive SNP-based tests to capture
each DQ type in the extended CEU analysis panel (Utah residents
with northern and western European ancestry). We first found the
SNPs that have the highest r2 to a DQ type. We proceeded with
multi-SNP (haplotype) tests to achieve higher r2 with which a DQ
type was captured (if r2 ,1). For DQ2.2, multiple SNPs were
needed that in combination capture this HLA allele. Since there is
a lot of variation in the MHC region that can interfere in primer
annealing, we only selected SNPs that could be typed using
conventional methods (e.g. Taqman).
Tag SNP typing
The tag SNPs in all samples except for the UK cohort were
obtained as Assay on Demand (rs2395182, rs4713586, rs4639334)
or Assay by Design (rs7454108, rs7775228, rs2187668) from
Applied Biosystems (Applied Biosystems, Foster City, California,
USA) (see Table S1 for assay numbers or primer sequences and
their allele labeling). Samples were genotyped using the manufac-
turer’s instructions and analyzed on an ABI PRISM 7900 HT
system (Applied Biosystems). All SNPs were typed using the
standard amplification protocol as supplied by Applied Biosystems.
We obtained end-point measurements for the analysis. Dropout
rates were below 3.57% and are shown in Table S1 for each
individual SNP. No Mendelian errors were observed for the SNPs
in the trio control cohort. Genotyping of rs2187668 SNP in UK
samples was obtained as part of a genome-wide association study
using the Illumina 300K chip [21].
Analyses
The HLA-DQA1 and -DQB1 genotypes as determined at the
HLA-typing centres were used to establish the corresponding DQ
types (see Figure 1). Due to the high linkage disequilibrium in the
MHC region, only a limited set of DQA1*-DQB1* haplotypes
(DQ types) are observed in the general population (see http://
depts.washington.edu/rhwlab/resMat/dq/linkage.html for an ex-
ample of common combinations of DQA1* and DQB1* alleles in
the Caucasian population), resulting in only a few instances that
did not correspond to canonical DQ types. For the prediction
method we inferred DQ types from the tag SNPs. DQ types were
determined according to the predicting alleles (see Table 3, e.g. a
person was called homozygous DQ8 if rs7454108 was homozy-
gous G, or heterozygous DQ8 if rs7454108 was heterozygous G/
A). Only individuals with non-missing data were used for
comparing the official typing and the prediction method. DQ
types based on the official typing and those from the tag SNP
typing method were compared to examine the sensitivity,
specificity, positive predictive value (PPV) and r2.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0002270.s001 (0.05 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0002270.s002 (0.13 MB
DOC)
Table S3
Found at: doi:10.1371/journal.pone.0002270.s003 (0.05 MB
DOC)
Table S4
Found at: doi:10.1371/journal.pone.0002270.s004 (0.08 MB
DOC)
Acknowledgments
We thank all healthy individuals, the patients, their physicians, and the
Dutch Coeliac Disease Foundation for participating in this study. We thank
Harry van Someren as database manager and Jackie Senior for critically
reading the manuscript.
Author Contributions
Conceived and designed the experiments: CW. Performed the experi-
ments: AM AZ DP JR. Analyzed the data: AM AZ. Contributed reagents/
materials/analysis tools: Pd WV Dv BC RA AL. Wrote the paper: Pd CW
AM AZ.
Table 3. DQ molecules and tested tag SNPs
DQ type DQA1 DQB1 DR tag SNP Positive predicting allele(s) (freqCEU) tag SNP Negative predicting allele
DQ2.2 0201 0202 7 rs2395182, rs7775228 T (0.71), G (0.10) rs4713586 G (0.025)
DQ2.5 0501 0201 3 rs2187668 T (0.09)
DQ7 0505 0301 5 rs4639334 A (0.09)
DQ8 0301 0302 4 rs7454108 G (0.18)
a) DQ molecules, the corresponding HLA-DQA1* and -DQB1* alleles, with the DR type and the tag SNPs. A person that has the T,G,A haplotype for rs2395182, rs7775228,
rs4713586, is a DQ2.2.
A person that has the T,G,G haplotype for rs2395182, rs7775228, rs4713586, is not a DQ2.2 but a DQ4.
Freq(CEU) – frequency of annotated alleles in CEU HapMap population
doi:10.1371/journal.pone.0002270.t003
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